Canakinumab in gout

Bibliography

• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007 – 2008. Arthritis Rheum 2011;63(10):3136-41
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009;48(Suppl 2):ii9-ii14
   PubMed Web of Science ®Google Scholar
• Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010;69(11):1907-12
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24
   PubMed Web of Science ®Google Scholar
• Jordan KM, Cameron JS, Snaith M, British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4
   PubMed Web of Science ®Google Scholar
• Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008;10:218-27
   PubMedGoogle Scholar
• Wertheimer AI, Davis MW, Lauterio TJ. A new perspective on the pharmacoeconomics of colchicine. Curr Med Res Opin 2011;27:931-7
   PubMed Web of Science ®Google Scholar
• Colcrys(R) (colchicine) package insert. AR Scientific, Inc; Philadelphia, PA: 2011
   Google Scholar
• Ahern MJ, Reid C, Gordon TP, Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987;17:301-4
   PubMedGoogle Scholar
• Terkeltaub RA, Furst DE, Bennett K, High versus low dosing of oral colchicine for early acute gout flare. Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8
   PubMed Web of Science ®Google Scholar
• Fam AG. Current therapy of acute microcrystalline arthritis and the role of corticosteroids. J Clin Rheumatol 1997;3:35-40
   PubMedGoogle Scholar
• Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416
   PubMed Web of Science ®Google Scholar
• Rubin BR, Burton R, Navarra S, Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Boice JA, Daikh DI, Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br Med J 2002;324:1488-92
   PubMed Web of Science ®Google Scholar
• Schumacher HR, Chen LX. The practical management of gout. Clevel Clin J Med 2008;75(Suppl 5):S22-5
   PubMedGoogle Scholar
• Eggebeen AT. Gout: an update. Am Fam Physician 2007;76:801-8. 811-812
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arth Res Ther 2006;8(Suppl1):S3
   PubMed Web of Science ®Google Scholar
• Neogi T. Gout. N Engl J Med 2011;364:443-52
   PubMed Web of Science ®Google Scholar
• Kineret(R) (anakinra) package insert. Biovitrum AB, Stockholm; Sweden: 2009
   Google Scholar
• Arcalyst(R) (rilonacept) package insert. Regeneron Pharmaceuticals, Inc; Tarrytown, NY: 2010
   Google Scholar
• Ilaris(R) (canakinumab) package insert. Novartis Pharmaceuticals Corporation; East Hanover, NJ: 2011
   Google Scholar
• Lachmann HJ. In: Couillin I, Petrilli V, Martinon F, editors. The inflammasomes (Progress in Inflammation Research). 1st edition. Springer Basel; Basel, Switzerland: 2011. p. 209-20
   Google Scholar
• So A, De Smedt T, Revaz S, A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Sundy JS, Schumacher HR, The interleukin 1 inhibitor rilonacept in the treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-17
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Schumacher HR, Curtis C, Evaluation of rilonacept in patients with gouty arthritis experiencing an acute gout attack [abstract]. Arthritis Rheum 2010;62(Suppl 10):153
   Google Scholar
• Schumacher HR, Sundy JS, Terkeltaub R, Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase 2 clinical trial. Arthritis Rheum 2012;64(3):876-84
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-IL-1B monoclonal antibody. Clin Pharmacokinet 2012;51(6):e1-e18
   PubMedGoogle Scholar
• So A, De Meulemeester M, Pikhlak A, Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Arthritis Rheum 2010;62:3064-76
   PubMed Web of Science ®Google Scholar
• Schlesinger N, Lin Liao HY, De Meulemeester M, Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol therapy: results of a double-blind, randomised study. Ann Rheum Dis 2011;70:1264-71
   PubMed Web of Science ®Google Scholar
• Schlesinger N, Alten R, Bardin T, Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomized multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; Epub ahead of print
   PubMedGoogle Scholar